Heidelberg Pharma AG
WILEX AG: Subsidiary Heidelberg Pharma contracts Suisse CDMO Celonic for antibody cell line development and antibody production
DGAP-News: WILEX AG / Key word(s): Alliance PRESS RELEASE WILEX AG: Subsidiary Heidelberg Pharma contracts Suisse CDMO Celonic for antibody cell line development and antibody production
Munich, Germany, 27 September 2016. WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE), today announced that its subsidiary Heidelberg Pharma, has signed an agreement with Celonic AG, Basel, Switzerland, a specialist in the development and manufacturing of biologics (CDMO). This agreement includes cell line development and the production of non-GMP and GMP (Good Manufacturing Practice) batches of antibody material to be used in the manufacture of clinical material of Heidelberg Pharma’s first ATAC (Antibody Targeted Amanitin Conjugate) candidate HDP-101 to treat multiple myeloma. HDP-101, an antibody drug conjugate, combines a BCMA antibody that specifically recognizes a highly expressed target on malignant plasma cells with a linker and the chemically coupled toxic payload Amanitin for the potential treatment of multiple myeloma. BCMA antibodies were originally developed by the Max Delbrück Center in Berlin and then adapted for the proprietary ATAC technology of Heidelberg Pharma. Based on promising preclinical data, Heidelberg Pharma has decided to further advance HDP-101 into IND-enabling studies. Multiple myeloma is the third most common and often incurable hematologic malignancy with a significant unmet medical need for this patient population. Professor Andreas Pahl, Head of Research & Development and member of the Management Board of WILEX and Heidelberg Pharma, commented: “With this contract, Heidelberg Pharma starts the cooperation with different partners involved in developing and manufacturing ATACs towards clinical application. We are pleased to work with Celonic, which offers cell lines that are proven to be particularly robust and efficient and are also suited to GMP processes.” Vikalp Mohan, Vice President Global Commercial Operations at Celonic mentioned: “Celonic is excited to partner with Heidelberg Pharma as it prepares for the clinical development of its first ATAC candidate. The development and production of this antibody requires an excellent development platform, process efficiency and proven manufacturing expertise. This is exactly what Celonic stands for. We are committed to supporting Wilex AG in achieving its project objectives.” About Heidelberg Pharma’s proprietary ATAC technology About WILEX and Heidelberg Pharma About Celonic
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
2016-09-27 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English | |
Company: | WILEX AG | |
Grillparzerstr. 18 | ||
81675 München | ||
Germany | ||
Phone: | +49 (0)89 41 31 38 – 0 | |
Fax: | +49 (0)89 41 31 38 – 99 | |
E-mail: | info@wilex.com | |
Internet: | www.wilex.com | |
ISIN: | DE000A11QVV0 | |
WKN: | A11QVV | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange | |
End of News | DGAP News Service |